Similar Articles

Browse Main Topics:

Business
Computers & Electronics
Education & Reference
Entertainment & Leisure
Family & Home
Finance & Investment
Health
Internet
Pets & Animals
Science & Technology
Society, Politics & Culture
Sports & Recreation

Similar Articles

The Motley Fool December 14, 2010 Esterhuizen & Sellitti	2011 Momentum Trades: 8 Huge Rallies Being Chased by the Smart Money Here's a list of stocks that momentum traders may want to keep an eye on.
The Motley Fool June 2, 2009 Brian Orelli	ASCO's Big Winner Despite the massive changes in value that some small-cap biotech companies have seen before and during this year's American Society of Clinical Oncology annual meeting, the big winner from the confab is actually large pharmaceutical companies.
The Motley Fool September 30, 2008 Brian Lawler	Moody's Gets Moody With Drugmakers European pharmaceuticals get a negative rating from Moody's.
The Motley Fool November 22, 2010 Esterhuizen & Sellitti	Profiting From European Panic: 6 Stocks Being Snapped Up by the Smart Money Could Europe's woes have a global reach? Short-term concerns present an opportunity in some of these European companies.
The Motley Fool April 29, 2005 Charly Travers	Value in Drug Stocks? Looking at some big pharma companies and liking what you see? Take a peek at biotech, too. GlaxoSmithKline... Pfizer... Amgen... Genzyme... etc.
Pharmaceutical Executive November 1, 2011	Turbulent Waters: M&As 2011 The latest numbers in pharma deals reveals a sector in transition, where market volatility has sharply degraded the appetite for risk.
Pharmaceutical Executive August 1, 2006 Patrick Clinton	From the Editor: Take Your Seat There's a lot to accomplish in the pharmaceutical industry. But considering what the industry has done in 25 years, it's not impossible.
BusinessWeek November 29, 2004 Catherine Arnst	Big Pharma's Blinders Hugely profitable thanks to a few blockbusters, Big Pharma is far too focused on looking for the next best-seller, causing companies to pass up opportunities to deliver important breakthroughs.
The Motley Fool April 21, 2004 Ben McClure	Discount Pharmacy With prices beaten down across the pharmaceuticals industry and the quarterly reporting season here, do any investment opportunities pop up?
The Motley Fool September 9, 2004 Charly Travers	The Case for Drug Stocks The reports of the drug industry's death are greatly exaggerated.
The Motley Fool December 20, 2007 Brian Orelli	2007: The Year Pharma Fell in Love With Biologics The reason for pharma's newfound infatuation for biotech is quite clear. Many pharmaceutical companies are facing a patent cliff in the coming years, and they need to replace their blockbusters with something.
The Motley Fool December 29, 2006 Brian Lawler	Lilly's Patents Stay in Bloom Even with upcoming patent expiries, Lilly isn't in nearly the same desperate situation that some of its large-cap pharma peers will be dealing with in the upcoming years. Investors, take note.
The Motley Fool December 21, 2004 Charly Travers	Invest With Fewer Side Effects Averse to risk? Check out these nontraditional drug companies: Biogen Idec... Elan... Salix Pharmaceuticals... Atrix Laboratories... etc.
The Motley Fool June 25, 2009 Brian Orelli	Loss of a Settlement Option Earlier this month the Federal Trade Commission came out with a report arguing for limited patent protection for drugs made by biotech companies. Now it's ratcheting up its complaints about pharmaceutical and generic-drug companies as well.
Pharmaceutical Executive December 1, 2008 Patrick Clinton	Reason to Believe Here are a few things to be optimistic about in the pharmaceutical industry.
The Motley Fool December 16, 2011 Rebecca Lipman	Covidien Spins Off Drug Company: 5 Drug Makers Hedge Funds Want Most The "smart money" thinks these drug companies have more upside than downside.
Knowledge@Wharton	The Benefits Are Mutual in New Wave of Biotech/Pharma Alliances The spat that erupted between pharma giant Bristol-Myers Squibb and biotech firm ImClone Systems over their partnership to develop a new cancer drug put the structure of alliances between discovery research firms and big drug makers under a microscope...
The Motley Fool February 22, 2005 Brian Gorman	Novartis Embraces Generics The company is taking a different path from its branded pharmaceutical peers. The company's strategy may make its stock worth a closer look.
The Motley Fool November 30, 2010 Esterhuizen & Sellitti	Overblown Fears: Eurocentric Companies Being Snapped Up by the Smart Money Are Europe's woes creating good investing opportunities?
The Motley Fool November 30, 2010 Brian Orelli	A Witty Response to Pharma's R&D Dilemma According to GlaxoSmithKline CEO Andrew Witty, the pharmaceutical industry is a mess. That's the basic gist of his opinion piece in The Economist.
The Motley Fool January 10, 2011 Esterhuizen & Sellitti	Top 5 Retail Stocks Being Snapped Up by the Smart Money Find out how to give your portfolio an exposure to the rebounding retail sector.
The Motley Fool August 27, 2010 Travers & Jayson	The Most Important Thing about Regeneron Pharmaceuticals Stop obsessing about the science.
BusinessWeek February 27, 2006 Einhorn & Kripalani	In India, Selling Generics Used To Be So Easy Suddenly, Indian drugmakers Dr. Reddy's and Ranbaxy have a host of copycat rivals.
The Motley Fool February 28, 2011 Brian Orelli	Pharma's Newest Acquisition Targets Share buybacks are in at big pharma companies. Does it mean that licensing deals are out?
The Motley Fool August 17, 2010 Travers & Jayson	Is Alexion Pharmaceuticals Burning Out? The first step toward finding a promising biotech company is not to figure out whether the science is any good, but to make sure that the company is financially healthy.
The Motley Fool August 26, 2010 Travers & Jayson	Will Onyx Pharmaceuticals Burn You? Is Onyx Pharmaceuticals on strong financial footing?
The Motley Fool March 4, 2004 Brian Gorman	Biotech Is Back Biotech financing is on a roll. But before you jump into the sector, learn some lessons from the past. Companies that enter the market earlier in the boom are better positioned than those that start later, and it's best to choose firms with late-stage drug candidates.
The Motley Fool June 26, 2006 Stephen D. Simpson	Is Novartis the Future of Generics? Merck's recent pricing action might just be the beginning of the end of generics as we know them. Investors, take note.
The Motley Fool May 18, 2010 Brian Orelli	What Astellas' Purchase of OSI Means for Biotech Investors Stop buying for the potential takeout.
The Motley Fool July 14, 2008 Brian Orelli	Teva Gets a Taste of Its Own Medicine Momenta Pharmaceuticals and Novartis are challenging the patents on Teva Pharmaceutical's blockbuster multiple sclerosis drug Copaxone.
The Motley Fool August 17, 2010 Travers & Jayson	How Long Can Amylin Pharmaceuticals Last? You don't need an advanced degree in pharmacology to find biotech companies with a legitimate chance of hitting it big.
The Motley Fool January 24, 2006 Stephen D. Simpson	Reddy, Set, Go! After a tough stretch, leading Indian pharmaceutical company Dr. Reddy's may be ready to move again. This is still a turnaround story, though, so investors unable or unwilling to assume above-average risk should probably steer clear.
The Motley Fool December 14, 2004 Charly Travers	Genetics of a Rule Breaker Investing is a lifelong learning process. We never know everything, but it is important we strive to learn from the lumps we take along the way. Here are some hard-earned tips from a biotech investor.
The Motley Fool August 18, 2010 Travers & Jayson	Will Endo Pharmaceuticals Holdings Burn You? Endo Pharmaceuticals Holdings is cash flow-positive, and has been for quite some time. That's investment nirvana for biotech shareholders.
The Motley Fool April 22, 2011 Sean Williams	Pharma's Most Perilous Pipelines Patent expirations expose weaknesses for these Wall Street darlings.
Pharmaceutical Executive August 1, 2005 Jill Wechsler	Washington Report: Treating Patents It may seem unusual that a court ruling challenging patent protections is considered a victory for Big Pharma. But the decision was supported by pharmaceutical companies, along with the Justice Department, as a way to spur biomedical research and new-drug development.
The Motley Fool August 24, 2010 Travers & Jayson	Will Valeant Pharmaceuticals Burn You? How well has Valeant Pharmaceuticals International tapped the capital markets? Here's a visual summary of the past few years
The Motley Fool August 18, 2010 Charly Travers & Seth Jayson	Will United Therapeutics Burn You? United Therapeutics is cash flow-positive and has mostly been over the past few years. That's investment nirvana for biotech shareholders. This is a rare beast worthy of additional research.
Pharmaceutical Executive October 1, 2010	Taking a Less-Generic Route to Generics A leading pharmaceutical industry player speaks out on what is fueling success in the sector.
The Motley Fool February 28, 2008 Brian Lawler	Benefiting From 2008's Generic Drugs While drug companies scramble to make up for lost revenue as their products are hit with patent expirations, other companies will benefit from the patent losses. Take a look at some winners and losers of drugs going off patent this year.
The Motley Fool November 2, 2010 Travis Hoium	Momenta Pharmaceuticals Shares Plunged: What You Need to Know Momenta Pharmaceuticals shares fell 10% in trading early Tuesday after Teva Pharmaceutical Industries said it expects FDA approval this year on a drug to compete with Momenta's enoxaparin.
Chemistry World October 21, 2011 Sarah Houlton	Abbott Splits to Set Pharma Portfolio Free Abbott Laboratories is to be split in two and claims the aim is to strengthen the outlook for growth and shareholder returns.
The Motley Fool March 27, 2009 Brian Orelli	Trading Up With the $95 From Genentech Genentech is gone; here's what you should replace it with.
The Motley Fool December 19, 2005 Stephen D. Simpson	Pfizer Wins, a Sector Rejoices The pharmaceutical dodges a bullet and investors find renewed enthusiasm for big-cap pharma.
The Motley Fool November 17, 2010 Esterhuizen & Sellitti	Emerging Trends: 4 Mexican Stocks Seeing Institutional Buying Investing in emerging market stocks presents some unique challenges.
Pharmaceutical Executive October 1, 2005 Brad Miles	Value Today for Drugs Tomorrow The industry can help its bad rep by communicating the promise of its pipeline -- and the value of its companies.
The Motley Fool April 24, 2006 Stephen D. Simpson	Novartis: A Good Story Repeated Whether sales were a little light or not, this is still a high-quality pharmaceutical company. The company not only has a good pipeline, but the valuation is still attractive without needing to make particularly aggressive assumptions.
The Motley Fool July 14, 2005 Stephen D. Simpson	These Swiss Don't Miss Aside from a hiccup in margins, Novartis' drug business continues to shine. This pharma is a solid middle-of-the-road play with reasonable valuation, a solid pipeline, and a not-so-secret weapon in its Sandoz generics business.
The Motley Fool September 11, 2007 Brian Lawler	Where Momenta Stands Momenta Pharmaceuticals updates investors as to the status of drugs in its pipeline. Until the FDA makes up its mind on its lead drug, an anticoagulant, it's anyone's guess as to what the value of the pipeline is. Investors should take note.
Inc. May 1, 2002 Kenneth Klee	The Industry You Can't Afford to Miss After more than two decades of hype, hope, disappointment, and progress, the hundreds of mostly small, money-burning companies that make up the biotech industry are experiencing a decisive shift in their relationship with the giant, rich pharmaceutical companies...